Kiek dividendų moka EKF Diagnostics Holdings 2024?
Pagal paskutinę informaciją nuo lapkritis 2024, EKF Diagnostics Holdings per paskutinius 12 mėnesių mokėjo bendrą dividendą, kuris sudarė 0,01 GBP už akciją. Esant dabartiniam EKF Diagnostics Holdings kursui 0,27 GBP, tai atitinka 4,44 % dividendų grąžą.
Dividendai mokami kartus per metus.
4,44 % Dividendo grąža | = | 0,01 GBP Dividendas | 0,27 GBP akcijų kaina |
|
Ar EKF Diagnostics Holdings dividendai yra saugūs?
EKF Diagnostics Holdings kasmet didina dividendus jau 3 metus.
Per pastaruosius 10 metus EKF Diagnostics Holdings kasmet 0 % sumažinta.
Per 5 metų laikotarpį krito išmokos padidėjo 0 %.
Analitikai prognozuoja, kad einamaisiais verslo metais Dividendų mažinimas bus −4,463%.
EKF Diagnostics Holdings Aktienanalyse
Ką daro EKF Diagnostics Holdings?
EKF Diagnostics Holdings PLC is a service business that offers a wide portfolio of diagnostics, medical devices, and point-of-care systems. It is an international company that sells its products in more than 100 countries worldwide. The company has offices in North America, Europe, and Asia-Pacific. EKF Diagnostics Holdings PLC was formed in 2010 through the merger of three diagnostic companies.
The history of EKF Diagnostics Holdings PLC began in 1990 with the founding of Hemocontrol. This company developed innovative devices for monitoring blood coagulation in patients with red blood cell abnormalities. In 1995, Dade Behring Diagnostics (DBD) was established as a subsidiary of Hemocontrol, specializing in the manufacture and marketing of diagnostic products. DBD quickly became a major player in the global diagnostics market and was acquired by Siemens in 2006. In 2001, Pointe Scientific was founded, a company focused on the development and production of high-quality diagnostic tests and instruments.
The current business model of EKF Diagnostics Holdings PLC is based on four key areas: Diabetes Care, Point-of-Care, Central Lab, and Life Sciences. All four areas aim to develop and offer innovative solutions for better patient care.
The Diabetes Care segment offers diagnostic products for monitoring diabetes. It includes HemoScan, a device for measuring hemoglobin A1C, a test that measures blood sugar levels over several months, enabling the diagnosis and monitoring of diabetes.
The Point-of-Care segment offers tests and devices for performing diagnoses and treatments directly at the point of care. This includes devices for measuring blood sugar and cholesterol, as well as devices for determining hemoglobin or troponin.
The Central Lab segment offers a wide range of diagnostic tests and instruments for determining blood chemistry, hematology, and immunology. This includes autoanalyzers, hemoglobin counters, and blood glucose meters.
The Life Sciences segment offers a wide range of diagnostic tests, instruments, and reagents. This includes tests for cancer diagnosis and monitoring thyroid function.
The company offers a variety of products to ensure optimal patient care. This includes diagnostic tests for determining infectious diseases or monitoring chronic conditions.
EKF Diagnostics Holdings PLC is a company that is constantly evolving and strives to offer innovative products and solutions. The company places great emphasis on research and development to stay at the forefront of the changing market. The company has an experienced team of technicians and scientists dedicated to the development, production, and marketing of diagnostic products. EKF Diagnostics Holdings yra viena populiariausių įmonių Eulerpool.com svetainėje.Akcijų taupymo planai siūlo patrauklią galimybę investuotojams ilgalaikėje perspektyvoje kurti turtą. Vienas pagrindinių privalumų yra vadinamasis vidutinės išlaidos efektas: reguliariai investuojant fiksuotą sumą į akcijas arba akcijų fondus, automatiškai perkama daugiau dalinių vertybių popierių, kai kainos yra žemos, ir mažiau – kai jos aukštos. Tai gali lemti palankesnę vidutinę dalies kainą per laiką. Be to, akcijų taupymo planai suteikia galimybę ir smulkiesiems investuotojams patekti į brangias akcijas, nes jie gali dalyvauti jau su mažomis sumomis. Reguliarus investavimas taip pat skatina disciplinuotą investavimo strategiją ir padeda išvengti emociškai pagrįstų sprendimų, pavyzdžiui, impulsyvaus pirkimo ar pardavimo. Be to, investuotojai gauna naudos iš potencialaus akcijų vertės augimo bei iš dividendų, kurie gali būti reinvestuoti, kas sustiprina sudėtinio palūkanų efektą ir taip skatina investuoto kapitalo augimą.